News for Arch Biopartners Inc. (ARCH.V)

TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (”œArch” or the ”œCompany”) (TSX Venture: ARCH and ACHFF) announced today that the inv

Arch Biopartners (OTCQB: ACHFF) launches Phase II PONTIAK trial for preventing AKI. The study will recruit 698 patients in Alberta, Canada, with $1.9 mi

TORONTO, July 22, 2025 (GLOBE NEWSWIRE) —

**media[566984]**

TORONTO, March 05, 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a …

**media[509223]**

**media[462036]**

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a n…

TORONTO, July 29, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a n…

TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced toda...

British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney…

TORONTO, March 15, 2024 (GLOBE NEWSWIRE) —

TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) —

TORONTO, Dec. 21, 2023 (GLOBE NEWSWIRE) —

TORONTO, Dec. 18, 2023 (GLOBE NEWSWIRE) —